BTIG Lowers Exact Sciences Price Target to $60, Maintains Buy Rating

BTIG analyst Mark Massaro has lowered the price target for Exact Sciences (EXAS) to $60 from $65, while maintaining a Buy rating. The firm is positive about the outlook for both Exact Sciences and Freenome following their deal. Exact Sciences has quickly pivoted from a setback in its blood program and de-risked the threat of competition from Guardant Health.

BTIG analyst Mark Massaro has recently lowered the price target for Exact Sciences (EXAS) to $60 from $65, while maintaining a Buy rating. This adjustment follows a series of recent analyst actions and financial developments surrounding the company. The firm remains positive about the outlook for both Exact Sciences and Freenome following their recent deal.

Exact Sciences has been experiencing a mixed bag of analyst sentiment in recent months. While some analysts have maintained or raised their price targets, others have lowered them due to various concerns. RBC Capital, for instance, lowered its price target to $46.00 from $54.00, citing growth concerns and the company's ability to compete in the blood-based liquid biopsy testing market [1]. Similarly, TD Cowen lowered its price target to $66 from $75, while Piper Sandler maintained its $70 target [2].

The company's strong second-quarter 2025 earnings, which exceeded analyst expectations, have not been enough to sway all analysts. Exact Sciences reported an EPS of -$0.01, compared to the anticipated -$0.13, and revenue of $811.1 million against expectations of $773.8 million. Despite these positive results, some analysts remain cautious due to setbacks in the company's blood test program and concerns about competition from Guardant Health [1].

The recent deal between Exact Sciences and Freenome to commercialize Freenome's blood-based screening test for colorectal cancer has been seen as a positive step by some analysts. The agreement, worth up to $885 million, is expected to accelerate market adoption of the CRC blood test, leveraging Exact Sciences' commercial infrastructure [3]. However, the long-term impact of this deal remains to be seen.

BTIG's Massaro, in his analysis, highlighted the potential benefits of the deal, stating that Exact Sciences has "quickly pivoted from a setback in its blood program and de-risked the threat of competition from Guardant Health." Despite this, the analyst's price target reduction suggests that there are still concerns about the company's ability to maintain its growth trajectory and compete in the market.

In conclusion, the mixed analyst sentiment and recent financial developments underscore the complex landscape of Exact Sciences' stock. While some analysts remain bullish, others are more cautious, reflecting the company's ongoing challenges and the uncertain future of its blood-based testing program.

References:
[1] https://www.investing.com/news/analyst-ratings/exact-sciences-stock-price-target-lowered-to-46-at-rbc-on-growth-concerns-93CH-4177664
[2] https://www.benzinga.com/insights/analyst-ratings/25/08/47029538/beyond-the-numbers-7-analysts-discuss-exact-sciences-stock
[3] https://www.freenome.com/newsroom/freenome-announces-exclusive-license-agreement-with-exact-sciences-to-commercialize-freenomes-blood-based-screening-test-for-colorectal-cancer/